WO2026119867 - ADAMTS13 IN THE TREATMENT OF DIABETIC RETINOPATHY
National phase entry is expected:
Publication Number
WO/2026/119867
Publication Date
11.06.2026
International Application No.
PCT/EP2025/085074
International Filing Date
02.12.2025
Title **
[English]
ADAMTS13 IN THE TREATMENT OF DIABETIC RETINOPATHY
[French]
ADAMTS13 DANS LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
OPDENAKKER, Ghislain
STRUYF, Sofie
Priority Data
24216862.3
02.12.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1962 | |
| EPO | Filing, Examination, Granting | 8450 | |
| Japan | Filing, Examination, Granting | 1890 | |
| South Korea | Filing, Examination, Granting | 1495 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,537
Contact Us
Abstract[English]
The invention relates to ADAMTS13 for use in the treatment or prevention of diabetic retinopathy in diabetes patients.[French]
L'invention concerne de l'ADAMTS13 destinée à être utilisée dans le traitement ou la prévention de la rétinopathie diabétique chez des patients atteints de diabète.